U.S. pharma big copyright scrapped two experimental weight loss products final yr—a when-daily tablet, lotiglipron, resulting from elevated liver enzymes as well as a twice-daily pill, danuglipron, resulting from solid side effects—but CEO Albert Bourla has said the company is decided to “Perform and win” while in the obesity space and in J